Clovis has confirmed a major victory with its ovarian cancer treatment Rubraca, the drug showing significant benefits for all patients in a maintenance setting – and better results than its rivals.

The price you pay for Rubraca may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the ...

The National Institute of Health and Care Excellence (NICE) has recommended pharmaand’s (pharma&) Rubraca (rucaparib) as a first-line maintenance treatment option for a subset of advanced ovarian ...

Clovis' Rubraca is on the verge of approval in Europe in women with advanced ovarian cancer, after regulators gave it the green light. The European Medicines Agency’s CHMP scientific committee ...